News
School of Pharmacy partners with Arch Therapeutics
The School of Pharmacy has entered into a new collaboration agreement with Arch Therapeutics, Inc., Wellesley, MA (OTCQB: ARTH) developer of the AC5 Surgical Hemostatic Device™, focusing on development of hemostasis and sealant products.
Arch is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. AC5TM is a unique product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “We are delighted to continue working with the team at the UCC School of Pharmacy. Since 2011, when we initiated the partnership, UCC has been an important part of our team. They have skilled scientists, enthusiastic PhD candidates and postdoctoral fellows who understand that academic institutions and industry can complement each other to fulfill unmet needs. They have a distinct model, not just in theory, but also in their ability to deliver on industry timelines. These collaborations are important steps for Arch’s planned footprint in Europe and we expect them to have positive implications for our Company and for the local Irish economy.”
Arch has developed a network of European and American collaborators in academic institutions and industry. As an example of Arch’s cooperative development model, this collaboration extends a successful multi-year relationship between Arch and institutions within NUI. A prior Arch collaboration with UCC, University College Dublin, and the Royal College of Surgeons in Ireland received support from the prestigious Science Foundation Ireland. In the current and prior partnerships, Arch leadership, technology and resources have combined with Irish academic institutional scientists and assets in order to drive product development.
Dr. Abina Crean, Lecturer of Pharmaceutics, School of Pharmacy, UCC said, “This collaboration with Arch Therapeutics is important. Dr. Norchi and his team brought a unique technology to its current near-commercialization status, and they have contributed novel insights and discoveries on peptide self-assembly to our partnership. Arch is focused on applications that should make a tremendous difference in the world of surgical and healthcare trauma, and we are pleased to factor into those efforts.”
Editors Notes:
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device ™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
Find out more at www.archtherapeutics.com.